Elan Corporation

AZACTAM® (aztreonam for injection, USP) is indicated for the treatment of the following infections caused by gram-negative organisms:

• Urinary tract infections, including pyelonephritis and cystitis
• Lower respiratory tract infections, including pneumonia and bronchitis
• Septicemia
• Skin and skin-structure infections
• Intra-abdominal infections, including peritonitis
• Gynecologic infections, including endometritis and pelvic cystitis                                 

IV/IM 500 mg, 1 g, 2 g

Single-dose 15 mL capacity vials (500 mg/vial; 1 g/vial; 2 g/vial)

Single-dose 100 mL capacity intravenous infusion bottles with bail bands (1 g/bottle; 2 g/bottle)

Also supplied as a frozen 50 mL single-dose intravenous solution (1 g/50 mL container; 2 g/50 mL container)

• Intra-abdominal infections, including peritonitis caused by susceptible strains of E coli, Klebsiella species including K pneumoniae, Enterobacter species including Enterobacter cloacae, * P aeruginosa, Citrobacter freundii,* and Serratia species* including S marcescens*.
• Lower respiratory tract infections, including pneumonia and bronchitis caused by susceptible strains of E coli, K pneumoniae, P aeruginosa, Haemophilus influenzae, Proteus mirabilis, Enterobacter species, and S marcescens*
• Urinary tract infections (complicated and uncomplicated), including pyelonephritis and cystits (initial and recurrent) caused by susceptible strains of E coli, K pneumoniae, P mirabilis, P aeruginosa, E cloacae, Klebsiella oxytoca,* Citrobacter species, and S marcescens*
• Skin and skin-structure infections, including those associated with postoperative wounds, ulcers, and burns caused by susceptible strains of E coli, P mirabilis, S marcescens, Enterobacter species, P aeruginosa, K pneumoniae, and Citrobacter species*
• Septicemia, caused by susceptible strains of E coli, K pneumoniae, P aeruginosa, P mirabilis,* S marcescens,* and Enterobacter species
• Gynecologic infections, including endometritis and pelvic cellulitis caused by susceptible strains of E coli, K pneumoniae,* Enterobacter species* including E cloacae,* and P mirabilis*                                 

Aztreonam References

Boucher, BA. Role of aztreonam in the treatment of nosocomial pneumonia in the critically ill surgical patient. Am J Surg. 2000; 179(suppl 2A):455-505.

Fabian TC, Hess MM, Croce MA, Wilson RS, et al. Superiority of aztreonam/clindamycin compared with gentamicin/clindamycin in patients with penetrating abdominal trauma. Am J Surg 1994; 167(3):291-296.

Polk HC, Jr., Livingston DH, Fry DE, Malangoni MA, et al. Treatment of pneumonia in mechanically ventilated trauma patients. Results of a prospective trial. Arch Surg 1997; 132(10):1086-1092.

Sader HS, Huynh HK, Jones RN. Contemporary in vitro synergy rates for aztreonam combined with newer fluoroquinolones and beta-lactams tested against gram-negative bacilli. Diagnostic Microbiology & Infectious Disease 2003; 47(3):547-550.